Q4
1.6.2022 15:02:07 CEST | Business Wire | Press release
Q4 Inc. (TSX: QFOR) (“Q4”), a leading capital markets communications platform provider, is excited to announce the launch of Q4 Capital Connect ™, a revolutionary, scalable platform built to streamline workflows and provide data-driven strategic insights across the capital markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005573/en/
Q4 Capital Connect™ enables public companies across all industries and market caps to seamlessly launch and measure the impact of a complete investor relations strategy. With one place to launch how they communicate their value to the markets, analyze the impact of every outreach, target and engage with the right investors, IR teams can build a repeatable, proactive strategy to connect with the capital markets. The platform approach allows all data generated by investors across an IR program to be aggregated alongside shareholder analytics for insights to shape a communication strategy that investors value while identifying and prioritizing the shareholders that matter.
The Q4 Capital Connect platform will house a portfolio of future applications, purpose-built to empower capital markets professionals. The first of these applications include Q4 Engagement Analytics and Q4 Web Management .
The Engagement Analytics application on Q4 Capital Connect™ aggregates the actions of investors and shareholders visiting an investor relations website and IR-related events, turning behavioral data into powerful leading indicators of stock movement, ownership data and surveillance to drive a new and proactive approach to investor targeting. Through these analytics, IROs can identify which new, existing or targeted institutions are assessing content, analyze interactions at the early stages of an investor’s research, prioritize their management team’s time to proactively engage with the right investor, and accelerate management’s awareness of activist interest in the company.
Engagement Analytics is the first product in the market that uniquely combines investor behavior with the buying and selling of publicly traded securities. This provides the ability to understand investors’ actions and intent on a daily basis and takes proactive targeting to a new level.
The fully integrated Web Management application on Q4 Capital Connect™ provides a frictionless and simplified approach to managing an IR website, offering one destination to request, track and approve critical updates to the market. Q4’s secure platform connects users with the Q4 Content Services team to easily request, preview, and publish changes to their website, while tracking change history in the same place. To date there are over 1,300 Q4 clients already using the web management application, who have experienced up to a 57% reduction in interactions when requesting content updates, a 35% improvement in turnaround times, and a vastly improved overall user experience.
“The launch of Q4 Capital Connect™ is just the beginning of a transformational approach to drive strategic, efficient and more effective interactions across the capital markets,” said Darrell Heaps, Q4’s CEO. “Built on proprietary data and analytics, along with an ever increasing portfolio of digital communication solutions, Q4 Capital Connect is a scalable platform that will continue to expand to an increasing number of applications for investor relations, as well as key workflows for investment banks and investors. We are very excited to introduce Q4 Capital Connect™ and demonstrate the strategic value and efficiencies we can provide to all capital markets participants when they come onto the Q4 platform.”
To learn more about Q4 Capital Connect™ please click here .
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors and investment banks make decisions to efficiently discover, communicate and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets CRM, shareholder and market analytics tools. The firm is a trusted partner to more than 2,700 public companies globally including many of the most respected brands in the world. Q4 is based in Toronto, with offices in New York and London. Learn more at q4inc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005573/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
